Company research
LB PHARMACEUTICALS INC
CIK 1691082Updated Nov 9, 2026
SecurityLBRX · NASDAQ · equity
Name history
LB PHARMACEUTICALS INC. · through Dec 12, 2018
LBRX price & chart
Loading TradingView…
NASDAQ:LBRX on TradingView ↗About the company
We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S. Food and Drug Administration, or FDA, for amisulpride were incompatible with patent coverage on the drug. Amisulpride is a generic drug that has been extensively used in clinical practice following its initial approval in France in the 1980s, generating at least two million monthly prescriptions in 2023 in a subset of 16 continental European countries. Among these European prescriptions for amisulpride, our data suggest that approximately 60% are for schizophrenia and schizoaffective disorders, approximately 20% are for mood d…
In the news
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G/A - filed by JPMORGAN CHASE & CO regarding LB PHARMACEUTICALS INC
EFFECT filing
POS AM filing
Show 5 more recent filings
S-3ASR filing
424B3 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
424B3 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| AssetsUSD | 320,746,000Source | — | 361,692,000Source | — | 393,482,000Source | — | 312,934,000Source | 33,534,000Source |
| Property, Plant and Equipment, NetUSD | 1,635,000Source | — | 2,204,000Source | — | 1,531,000Source | — | 1,581,000Source | 1,859,000Source |
| Current assets: | ||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 269,744,000Source | — | 283,111,000Source | — | 320,676,000Source | — | 250,173,000Source | 22,978,000Source |
| Assets, CurrentUSD | 316,401,000Source | — | 355,301,000Source | — | 389,074,000Source | — | 308,432,000Source | 28,879,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,922,000Source | — | 27,511,000Source | — | 23,438,000Source | — | 13,219,000Source | 880,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,198,000Source | — | 3,405,000Source | — | 2,101,000Source | — | 2,151,000Source | 2,298,000Source |
| LIABILITIES AND EQUITY | ||||||||
| LiabilitiesUSD | 10,525,000Source | — | 29,345,000Source | — | 14,789,000Source | — | 11,624,000Source | 13,829,000Source |
| Stockholders’ equity: | ||||||||
| Common Stock, Value, IssuedUSD | 3,000Source | — | 3,000Source | — | 3,000Source | — | 3,000Source | 1,000Source |
| Retained Earnings (Accumulated Deficit)USD | -118,056,000Source | — | -200,185,000Source | — | -148,582,000Source | — | -129,528,000Source | -104,323,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -53,000Source | — | 186,000Source | — | 208,000Source | — | 168,000Source | 111,000Source |
| Stockholders' Equity Attributable to ParentUSD | 310,221,000Source | -91,450,000Source | 332,347,000Source | -103,873,000Source | 378,693,000Source | -99,337,000Source | 301,310,000Source | -94,554,000Source |
| Additional Paid in Capital, Common StockUSD | 428,327,000Source | — | 532,343,000Source | — | 527,064,000Source | — | 430,667,000Source | 9,657,000Source |
| Liabilities and EquityUSD | 320,746,000Source | — | 361,692,000Source | — | 393,482,000Source | — | 312,934,000Source | 33,534,000Source |
| Current liabilities: | ||||||||
| Liabilities, CurrentUSD | 6,647,000Source | — | 23,564,000Source | — | 10,906,000Source | — | 7,442,000Source | 8,109,000Source |
| Operating Lease, Liability, CurrentUSD | 730,000Source | — | 844,000Source | — | 730,000Source | — | 730,000Source | 487,000Source |
| Accounts Payable, CurrentUSD | 2,590,000Source | — | 3,491,000Source | — | 7,119,000Source | — | 2,127,000Source | 2,320,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,936,000Source | — | 4,373,000Source | — | 2,740,000Source | — | 2,839,000Source | 3,216,000Source |
| Additional Financial Items | ||||||||
| Accrued Liabilities, CurrentUSD | 3,327,000Source | — | 19,229,000Source | — | 3,057,000Source | — | 4,585,000Source | 5,302,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 314,500,000Source | — | 324,897,000Source | — | 364,851,000Source | — | 295,203,000Source | 25,445,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | — | 321,000Source | 91,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,566,000Source | 634,000Source | 4,191,000Source | 3,090,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -23,290,000Source | -8,128,000Source | -35,208,000Source | -53,052,000Source |
| Cash flows from investing activities: | ||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -32,000Source | 4,980,000Source | -39,887,000Source | 23,234,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 32,000Source | 21,000Source | 52,000Source | 769,000Source |
| Cash flows from financing activities: | ||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 93,831,000Source | 0Source | 302,562,000Source | 38,315,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 70,509,000Source | -3,148,000Source | 227,467,000Source | 8,497,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 270,256,000Source | — | 283,893,000Source | — | 321,452,000Source | — | 250,943,000Source | 23,476,000Source |
| Additional Financial Items | ||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 314,500,000Source | — | 324,897,000Source | — | 364,851,000Source | — | 295,203,000Source | 25,445,000Source |
| Gain (Loss) on Sale of DerivativesUSD | — | — | — | — | — | — | -200,000Source | — | -1,161,000Source | 947,000Source |
| Gain (Loss) on Sale of InvestmentsUSD | — | — | — | — | — | — | 0Source | 119,000Source | 119,000Source | 955,000Source |
| General and Administrative ExpenseUSD | — | — | 2,827,000Source | 5,419,000Source | 9,769,000Source | 2,438,000Source | 7,459,000Source | 3,008,000Source | 13,660,000Source | 13,659,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 1,000Source | 1,000Source |
| Investment Income, InterestUSD | — | — | 707,000Source | 384,000Source | 2,974,000Source | 177,000Source | 2,850,000Source | 236,000Source | 3,920,000Source | 1,721,000Source |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | — | 0Source | 503,000Source | 0Source | 0Source | 0Source | 119,000Source | 119,000Source | 955,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,556,000Source | -14,181,000Source | -51,603,000Source | -4,871,000Source | -19,054,000Source | -5,306,000Source | -25,205,000Source | -63,102,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -3,556,000Source | -14,181,000Source | -51,603,000Source | -4,871,000Source | -19,054,000Source | -5,306,000Source | -25,205Source | -63,102Source |
| Nonoperating Income (Expense)USD | — | — | 1,690,000Source | 1,902,000Source | 2,312,000Source | -12,000Source | 3,050,000Source | 1,123,000Source | 5,200,000Source | 1,729,000Source |
| Operating ExpensesUSD | — | — | 5,246,000Source | 16,083,000Source | 53,915,000Source | 4,859,000Source | 22,104,000Source | 6,429,000Source | 30,404,000Source | 64,830,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | — | — | 2,500,000Source | 30,100,000Source |
| Depreciation | — | — | — | — | — | — | —Source | —Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -3,556,000Source | -14,181,000Source | -51,603,000Source | -4,871,000Source | -19,054,000Source | -5,306,000Source | -25,204,000Source | -63,101,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 1,000Source | 1,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,556,000Source | -14,181,000Source | -51,603,000Source | -4,871,000Source | -19,054,000Source | -5,306,000Source | -25,205,000Source | -63,102,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.61Source | -39.49Source | -1.71Source | -13.58Source | -0.67Source | -14.79Source | -3.13Source | -176.15Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.61Source | -39.49Source | -1.71Source | -13.58Source | -0.67Source | -14.79Source | -3.13Source | -176.15Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 5,806,862Source | 359,079Source | 30,137,733Source | 358,811Source | 28,241,701Source | 358,777Source | 8,045,145Source | 358,229Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 5,806,862Source | 359,079Source | 30,137,733Source | 358,811Source | 28,241,701Source | 358,777Source | 8,045,145Source | 358,229Source |
| Additional Financial Items | ||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,000Source | 1,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | 300,000Source | 100,000Source |
| General and Administrative ExpenseUSD | — | — | 2,827,000Source | 5,419,000Source | 9,769,000Source | 2,438,000Source | 7,459,000Source | 3,008,000Source | 13,660,000Source | 13,659,000Source |
| Investment Income, InterestUSD | — | — | 707,000Source | 384,000Source | 2,974,000Source | 177,000Source | 2,850,000Source | 236,000Source | 3,920,000Source | 1,721,000Source |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | — | 0Source | 503,000Source | 0Source | 0Source | 0Source | 119,000Source | 119,000Source | 955,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -3,556,000Source | -14,181,000Source | -51,603,000Source | -4,871,000Source | -19,054,000Source | -5,306,000Source | -25,205Source | -63,102Source |
| Nonoperating Income (Expense)USD | — | — | 1,690,000Source | 1,902,000Source | 2,312,000Source | -12,000Source | 3,050,000Source | 1,123,000Source | 5,200,000Source | 1,729,000Source |
| Operating ExpensesUSD | — | — | 5,246,000Source | 16,083,000Source | 53,915,000Source | 4,859,000Source | 22,104,000Source | 6,429,000Source | 30,404,000Source | 64,830,000Source |
| Research and Development ExpenseUSD | — | — | 2,419,000Source | 10,664,000Source | 44,146,000Source | 2,421,000Source | 14,645,000Source | 3,421,000Source | 16,744,000Source | 51,171,000Source |
Offerings
Registration 333-294900
Registration 333-299235
Registration 333-289812
- Gross proceeds
- 285000000.0
- Net proceeds
- 265050000.0
- Deal price
- 15.0
- Shares
- 19000000
- Offering price
- $15.00
- Ticker
- LBRX
Filing attachments
d167920dex991.htm · 8-K · 2026-11-05
Exhibit 99.1 LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update Strengthened leadership with the appointment of Susan G. Kozauer, M.D., as Chief Medical Officer and Joseph Miller as Chief Financial Officer On track for topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in 1H 2027 Presented new preclinical data supporting LB-102’s bimodal mechanism of action at the 39 th ECNP Congress Completed a private placement …
Read attachment ↗d171801dex44.htm · S-3ASR · 2026-10-01
Exhibit 4.4 LB PHARMACEUTICALS INC, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20__ Debt Securities T ABLE O F C ONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 …
Read attachment ↗d157620dex991.htm · 8-K · 2026-09-15
EX-99.1 2 d157620dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer NEW YORK, September 15, 2026 (GLOBE NEWSWIRE) - LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the appointment of Susan G. Kozauer, M.D. as Chief Medic…
Read attachment ↗d26110dex991.htm · 8-K · 2026-09-03
EX-99.1 2 d26110dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer NEW YORK, September 3, 2026 (GLOBE NEWSWIRE) - LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the appointment of Joseph Miller as Chief Financial Officer. Mr.…
Read attachment ↗d303033dex991.htm · 8-K · 2026-08-11
EX-99.1 2 d303033dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline expansion of LB-102 into new neuropsychiatric indications with strong mechanistic rationale and validating clinical and real-world experience from amisulpride Cash, c…
Read attachment ↗d156920dex41.htm · 8-K · 2026-07-29
EX-4.1 2 d156920dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (…
Read attachment ↗